港股異動 | 方達控股(1521.HK)大漲15%破頂 市值超120億港元
格隆匯1月22日丨方達控股(1521.HK)尾盤漲幅擴大至15%,報6港元創歷史新高價,市值超120億港元。今日港A股市場CRO概念股集體強勢,得益於逐年增長的醫藥研發投入和上升的滲透率,近年CRO行業迅猛發展。方達控股為港股中最便宜的CRO企業(行業估值看齊A股)。大股東中國臨牀CRO龍頭泰格醫藥持股50.94%;高瓴資本持股6.05%;上海景林資產、奧博資本為基石投資人。方達業務覆蓋藥物研發的全生命週期,在北美和中國的收入佔比為72.2%及27.8%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.